Podcasts about Cart

Revolutionizing Retail: Drew Ann Long's Caroline's Cart Journey In this episode of 'Why Not Me', hosted by Tony Mantor from Nashville, Tennessee Drew Ann Long shares her inspiring story of creating Caroline's Cart—a revolutionary shopping cart designed for individuals with special needs. Drew Ann, motivated by her daughter Caroline's severe disabilities, overcame numerous challenges, financial hurdles, and industry skepticism to bring her vision to life. Despite initial rejections from manufacturers, Drew's relentless pursuit led to global recognition and adoption of Caroline's Cart, transforming accessibility in retail. She also discusses the formation of Caroline's Cause, a nonprofit providing scholarships to families with special needs children. Drew's journey highlights the impact of empathy-driven innovation and the importance of taking bold risks to make a difference. Meet Drew Ann Long: Founder of Caroline's Cart The Birth of Caroline's Cart Challenges and Breakthroughs The First Prototype and Social Media Explosion Manufacturing Struggles and Success Nationwide and International Expansion Caroline's Cause: Giving Back Future Plans and Continued Growth Closing Thoughts and Contact Information Music written By T. Wild Mantor Music BMI The content on Why Not Me: Embracing Autism amd Mental Health Worldwide, including discussions on mental health, autism, and related topics, is provided for informational and entertainment purposes only. The views and opinions expressed by guests are their own and do not reflect those of the podcast, its hosts, or affiliates.Why Not Me is not a medical or mental health professional and does not endorse or verify the accuracy, efficacy, safety of any treatments, programs, or advice discussed.Listeners should consult qualified healthcare professionals, such as licensed therapists, psychologists, or physicians, before making decisions about mental health or autism- related care.Reliance on this podcast's contents is at the listener's own risk. Why Not Me is not liable for any outcomes, financial or otherwise, resulting from actions taken based on the information provided. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Sánchez comparece en el Senado y califica la comisión de circo, evadiendo preguntas clave con un recurrente "no me consta". Se le acusa de encenagamiento político y de no ofrecer explicaciones convincentes sobre su presunta implicación en casos de corrupción. En Pamplona, cuatro argelinos son detenidos por agresión sexual y robo. El embajador de Japón en España, Takahiro Nakamae, finaliza su misión, siendo reconocido por su dedicación al país. Se analiza que Sánchez sale vivo de la comparecencia, pero acorralado y sin ofrecer claridad. La inflación se dispara, afectando la luz, viajes y billetes de tren. En deportes, se juega la Copa del Rey y la Liga. A nivel internacional, Trump anuncia la reanudación de pruebas nucleares y se observa un deshielo comercial entre EE.UU. y China. El Hospital de La Paz presenta una terapia pionera con células CAR-T para la leucemia infantil, logrando resultados esperanzadores. COPE informa sobre la agenda de Madrid, incluyendo un dispositivo de ...

Para Pedro Henriques, VAR tinha de intervir para ajudar árbitro a dar vermelho direto ao jogador dos leões. Dá nota 4, arbitragem negativa, ficou cartão vermelho por mostrar.See omnystudio.com/listener for privacy information.

Para Pedro Henriques, VAR tinha de intervir para ajudar árbitro a dar vermelho direto ao jogador dos leões. Dá nota 4, arbitragem negativa, ficou cartão vermelho por mostrar.See omnystudio.com/listener for privacy information.

-SNAP benefits are running out due to the Schumer Shutdown, and Rob suggests giving to your local food bank — or preparing to ankle-tackle grocery thieves like a patriotic linebacker. -Between rants about the bourgeoisie, fentanyl, and golf carts, Rob declares the Democrat Party dead, buried, and possibly returning as a zombie by the midterms. Today's podcast is sponsored by : BEAM DREAM POWDER : Improve your health by improving your sleep! Get 40% off by using code NEWSMAX at http://shopbeam.com/NewsmaxGET FRESH OLIVE OIL : Try real farm fresh olive oils for FREE plus $1 dollar shipping at http://GetFreshRobCarson.comBIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday…E-mail Rob Carson at : RobCarsonShow@gmail.com Musical parodies provided by Jim Gossett (www.patreon.com/JimGossettComedy) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media:  -Facebook: http://nws.mx/FB  -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX  -Telegram: http://t.me/newsmax  -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices

Pedro Sánchez comparece en la comisión de investigación del Senado, donde el PP critica su actitud evasiva y su falta de colaboración. Sánchez acusa a la ultraderecha de atacar a las mujeres. Se analizan las consecuencias de esta comparecencia, con los aliados de Sánchez considerando que sale "indemne" y la oposición pidiendo su dimisión. Carlos Mazón, presidente de la Generalitat Valenciana, reflexiona sobre un evento pasado que genera más peticiones de dimisión. En noticias internacionales, se informa sobre un acuerdo entre Trump y Xi, la entrega de cuerpos por parte de Hamás, ataques rusos a Ucrania y detenciones por el robo del Louvre. A nivel nacional, cuatro detenidos por agresión sexual en Pamplona ingresan en prisión. La inflación de octubre sube al 3.1%. Se informan de complicaciones de tráfico en Madrid. El Hospital de la Paz anuncia un avance con células CAR-T en niños con leucemia. Miguel Tellado del PP critica duramente a Sánchez y su gobierno, afirmando que está ...

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

Senator Nessa Cosgrove on why she took her own 'snack cart' onto the Sligo train.

No episódio de hoje, vamos explorar tudo o que o Cartão Porto Bank Gold pode oferecer para o seu dia a dia. Você vai descobrir quais são os principais benefícios, como funcionam as vantagens exclusivas para clientes e de que forma esse cartão pode trazer mais praticidade e segurança para suas compras e viagens. Se você está pensando em solicitar o seu ou apenas quer entender melhor se vale a pena, este conteúdo é para você.Solicite o seu cartão de crédito https://tinyurl.com/7nm4exmrCÓDIGOS DE INDICAÇÃO CARTÃO DE CRÉDITOhttps://bit.ly/3RuEZ21GRUPO GRATUITO NO WHATSAPPhttps://tinyurl.com/5n79dtkmLivros sobre Educação Financeira https://amzn.to/47uuEY2Nosso site https://girofinanceiro.com.br/Canal do Youtube https://tinyurl.com/43jux7mr

In this episode, we dive into how to run the best promotions for Black Friday and Cyber Monday (BFCM). Nathan Ho, Product Manager of EasyGift, shares his experience and advice on structuring promotions, using tiered spending to increase average order value, and the power of free gifts. He also discusses different marketing strategies like scheduled rules and audience targeting to maximize sales during the busiest shopping days.Topics discussed in this episode:  How to start preparing for Black Friday as early as possible.What tiered minimum spend promotions are and why they work.Why a free gift is a strong trigger to encourage customers to buy more.How to use gifts as product samples to introduce new items.What scheduled rules are for setting time-specific deals.How to simplify promotions to avoid confusing your customers.What the classic promotion triggers are: cart value, products, and collections.How to use magic links to target new customers from ads.Why testing promotions before launch is critical to avoid conflicts.What optimizing shipping can do to stand out from competitors.Links & Resources Website: https://www.506.io/easygiftShopify App Store: https://apps.shopify.com/gifter-cart-auto-includeLinkedIn: https://www.linkedin.com/company/506-io/X/Twitter: https://twitter.com/506_appsGet access to more free resources by visiting the show notes at https://tinyurl.com/ab8jb8p3______________________________________________________ LOVE THE SHOW? HERE ARE THE NEXT STEPS! Follow the podcast to get every bonus episode. Tap follow now and don't miss out! Rate & Review: Help others discover the show by rating the show on Apple Podcasts at https://tinyurl.com/ecb-apple-podcasts Join our Free Newsletter: https://newsletter.ecommercecoffeebreak.com/ Support The Show On Patreon: https://www.patreon.com/EcommerceCoffeeBreak Partner with us: https://ecommercecoffeebreak.com/partner-with-us/

This week Emily gets artsy over the man behind CARTdepartment.         SHOW NOTES: Larry Warsh interview Jay Z, Kanye West Otis music video Lots of CART car pics  @cartdept Recorded, edited & mixed by Emdognightmare & Queen of the Vans Production & research Queen of the Vans & Emdognightmare Find us: Car Krush Stay updated w/ our newsletter Hugs, thank you & high fives to Greg Meleney for the killer tunez!

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped.  The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies.  Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve.   On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space.  BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next.   Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating. 

Cinco dicas para que você se blinde dos frequentes golpes.

As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing.Philip sits down with co-founder Gerrit Sitters to discuss the company's trajectory, the cyclic biotech investment market, and lessons from spinning the firm out from Vrije Universiteit Amsterdam.---Explore how LUMICKS' technology helps develop biologics and cell therapies with unique cell avidity data — http://bit.ly/lumicks---⭐️ ABOUT THE SPEAKERGerrit co-founded LUMICKS in 2014 following a PhD at Vrije Universiteit Amsterdam, and co-invented the technology behind LUMICKS' main products. Gerrit now serves as Head of Product, where he aims to deploy the company's products to tackle challenges in the life sciences.

durée : 00:05:32 - Le Billet politique - par : Stéphane Robert - Le Premier ministre, Sébastien Lecornu, estime qu'il n'a plus besoin du Sénat pour élaborer et faire adopter le budget de l'année prochaine. Il fait désormais le pari qu'il peut trouver une majorité à l'Assemblée nationale.

This month, the gals are joined by Trevin from Live, Laugh, Larceny Podcast to discuss a wiener catastrophe, poop spray damage, Sierra's stains, litter at the country club, a food critic for the people, and the most accident-prone pastor you've ever heard of. Tune in for October's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

Chroniqueurs : -Thomas Bonnet -Georges Fenech   Invité : -Jean-Yves Le Borgne, avocat Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode of ASTCT's Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy.From the groundbreaking ZUMA-1 trial to today's expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation. This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.

STF forma maioria em favor da nomeação de parentes para cargos políticos. Câmara pressiona por pacotes separados de contas e arrecadação após fim da MP. Sociedade médica lança novas recomendações para diagnóstico de autismo. Wagner Moura no palco no Rio e festival de teatro negro em SP. Rei Charles III e papa Leão XIV rezam juntos em encontro histórico. Essas e outras notícias, você escuta No Pé do Ouvido, com Yasmim Restum.See omnystudio.com/listener for privacy information.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael Wang, MD For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That's why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

As the potential of in vivo CAR-T therapy moves closer to clinical reality, biotech innovators are reimagining what's possible in autoimmune disease. With groundbreaking scientific advances and evolving regulatory perspectives, this next generation of cell therapy could redefine how immune-mediated conditions are treated. In this episode, Pete Robinson, Therapeutic Strategy Director, Novotech, joins Meredith Landry, Managing Editor, Custom Content, Citeline, to discuss how in vivo CAR-T is opening new possibilities for autoimmune therapies—and what it will take to translate early promise into patient impact. They explore: • The breakthrough potential of in vivo CAR-T—and what could make it a true game-changer for autoimmune disorders • Key developments and considerations to realize clinical success • Global landscape for early phase clinical trials

Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year. We're also talking about next-generation CAR T-cell therapy for MS, and we'll explain why it's such exciting news. We're sharing details about a DNA-based therapy for overactive bladder that just received fast-track status from the FDA. We'll tell you about a new effort to develop a simple blood test that will detect MS progression. We have some news to share about the RealTalk MS app. And we want to remind you to check out our ECTRIMS Extra Conversations video playlist on the RealTalk MS YouTube channel! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A deep dive into the research presented at ECTRIMS 2025  :22 Kernal Biologics received $48 million grant for the next-generation CAR T-Cell therapy  2:35 FDA grants fast track designation to DNA-based therapy to treat overactive bladder  6:02 Octave Bioscience receives grant to develop a blood test to detect MS progression  8:30 News about our app  9:42 Have you checked out our ECTRIMS Extra Conversations YouTube playlist?  10:30 Dr. Bruce Bebo discusses some of the most important research presented at ECTRIMS 2025  11:06 Share this episode  32:26 Next week's episode  32:47 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/425 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy LISTEN: RealTalk MS Ep 422: From ECTRIMS 2025 with Dr. Bruce Bebo and Kristine Werner Ozug https://realtalkms.com/422 WATCH: The RealTalk MS ECTRIMS Extra Conversations video playlist on YouTube https://realtalkms.com/ectrims2025 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 425 Guests: Dr. Bruce Bebo Privacy Policy

Cartógrafo, major e explorador, Percy Fawcett percorreu alguns dos lugares mais inóspitos do planeta. Em sua juventude, no Sri Lanka, explorou baías remotas e identificou ruínas de antigos reinos budistas.Quando adulto, trabalhou como espião para a Grã-Bretanha, investigando o sultão do Marrocos em Fez.Mas foi na Amazônia tornou-se famoso: Fawcett liderou expedições pelo Acre e pela Bolívia, ajudando a definir as fronteiras entre os dois países.Suas jornadas tornaram-se célebres, com seu rosto impresso em capas de jornais e revistas por toda Europa. Um tabloide da época dizia:“Esse é o verdadeiro escoteiro: tomem-o como exemplo! "O prestígio foi tanto que Leonard Darwin, filho de Charles Darwin e presidente da Royal Geographical Society, o levou em turnê para palestrar pela Inglaterra.Com chapéu de feltro, caderno de anotações e um jeito independente de trabalhar, Fawcett acabou se tornando o molde do aventureiro que mais tarde inspiraria personagens como Indiana Jones.Mas...nem todos o viam como um herói. Muitos colegas o consideravam rígido, arrogante e charlatão, um homem obcecado por glória pessoal e convicções quase absolutas sobre o território que explorava.E, de fato, havia muitas coisas sobre a vida de Fawcett que não era divulgada pela mídia geral...

A new regional campaign is encouraging residents across Chicagoland to “feed the cart” and help revive enthusiasm for recycling.

A new regional campaign is encouraging residents across Chicagoland to “feed the cart” and help revive enthusiasm for recycling.

A new regional campaign is encouraging residents across Chicagoland to “feed the cart” and help revive enthusiasm for recycling.

Hello my lovelies and welcome back to another episode of the pod, and another human being who changing the world! This time I am introducing you to Drew Ann Long, change-maker, world-builder and someone who does not believe in the word "NO", especially when one is trying to make this world better, and shinier, for everyone else! Drew is someone who believes deeply in the goodness in others, in her capacity for showing up for others, and oh, yeah, NEVER GIVING UP! To read about Drew and Caroline's Cart, and Caroline's Cause, click here!  To connect with her on Facebook, click here! Do yourself a favor, inspire yourself and remember, that each an every one of us has the ability to do BIG THINGS!! Be like Drew, in other words! PLEASE REMEMBER TO RATE AND REVIEW. IT'S A BIG DEAL AND MEANS SO MUCH TO ME! Your bit of beauty is this: this sweet and powerful YouTube video detailing her journey and her refusal to ever give up!

Hello my lovelies and welcome back to another episode of the pod, and another human being who changing the world! This time I am introducing you to Drew Ann Long, change-maker, world-builder and someone who does not believe in the word "NO", especially when one is trying to make this world better, and shinier, for everyone else! Drew is someone who believes deeply in the goodness in others, in her capacity for showing up for others, and oh, yeah, NEVER GIVING UP! To read about Drew and Caroline's Cart, and Caroline's Cause, click here! To connect with her on Facebook, click here! Do yourself a favor, inspire yourself and remember, that each an every one of us has the ability to do BIG THINGS!! Be like Drew, in other words! PLEASE REMEMBER TO RATE AND REVIEW. IT'S A BIG DEAL AND MEANS SO MUCH TO ME! Your bit of beauty is this: this sweet and powerful YouTube video detailing her journey and her refusal to ever give up!

Análise pós-jogo do BaVi válido pela 28ª rodada da Série A do Campeonato Brasileiro. Vem com a turma! Em jogo recheado de emoções, muitos cartões e grande festa da torcida rubro negra, deu vitória do Vitória! O resultado de 2 a 1 diante do Bahia deixa o Leão mais vivo do que nunca na briga […]

In this episode of The HemOnc Pulse, host Melissa speaks with Omar Nadeem, MD, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, about emerging genomic insights in smoldering multiple myeloma. The discussion focuses on recent research showing how molecular profiling can improve understanding of disease progression and refine risk stratification beyond traditional clinical models. Dr. Nadeem highlights how genomic data may help distinguish patients with smoldering myeloma who are at higher risk of progression from those likely to remain stable, offering the potential to guide more personalized treatment decisions. The conversation also explores the evolving landscape of precursor plasma cell disorders and the role of immunotherapy, including CAR T-cell therapy, in clinical management.      

Dr. Monty Pal and Dr. Fumiko Chino discuss several of the top abstracts presented at the 2025 ASCO Quality Care Symposium, including research on federally funded clinical trials and financial reimbursement for trial participation. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we are highlighting key abstracts that were presented at the 2025 ASCO Quality Care Symposium. I am delighted to be joined today by the chair of this year's meeting, Dr. Fumiko Chino. Dr. Chino is an associate professor in radiation oncology at MD Anderson Cancer Center with a research focus on access, affordability, and equity. She is also a consultant editor of JCO Oncology Practice and the host of the Put into Practice podcast. I have got to listen to that.  Dr. Chino, welcome, and thanks so much for being on the podcast today. Dr. Fumiko Chino: I am overjoyed to be here, and absolutely, you should take a listen. Dr. Monty Pal: Definitely. And FYI for listeners, our full disclosures are all available in the transcript of this episode, so do have a look if you are inclined. Now, we have really seen some fantastic advances in health services and quality and supportive care, digital health, and beyond. There are some great abstracts that were presented at this year's meeting. I have actually picked a couple that I am particularly interested in and that I believe you share my interest in as well.  So, the first is an abstract actually from my friends at SWOG (Abstract 94). So, this was a terrific abstract from Joe Unger and Michael LeBlanc and Dawn Hershman. And this, I think, really hits on a very, very key issue right now, which is the benefit of federally funded trials. Do you mind just kind of spelling out some of the observations from what I think is a really brilliant piece of work? Dr. Fumiko Chino: Absolutely, and I think Dr. Unger's work is really important for our current funding environment. I think that this research is really essential to do to show the role of federal sponsorship in the design and conduct of clinical trials. Because what they did was really look at a landscape analysis over the last 20 years looking at funding and were able to show quite clearly that federal funding really matters for advancing the science in cancer care. So what they showed was that the federal funding was more commonly essential for early-stage clinical trials, so those phase 1, phase 2 trials that really help advance the science. And that federal funding was really essential for multimodality drug combinations, combinations with drug and surgery, combinations with drug and radiation. Those trials were much more likely to be federal funded. And then the last thing is that they showed that the patients that are, I think, the largest at risk for gaps in care who really need the advancements in science that keep U.S. health care amazing and wonderful and world-leading, so the kids, the pediatric patients, the patients with rare cancers, and the patients actually that could benefit from de-escalation or right-sizing of treatment, they were also all more likely to have federal funding. So I think this research that was presented really shows that if, unfortunately, current status of restricted federal funding continues, that we are going to lose out in terms of the next generation of cancer cures, cancer de-escalations, and the type of combination treatments that make advancements in science. Dr. Monty Pal: Indeed. You know, I always point to Joe Unger's paper, and I think it is in JAMA Oncology, right, that showed life-years gained from NCI trials. It is such an important piece of work. I think this is a really nice complement to that, isn't it, to show the specific areas that otherwise would be, am I right in saying, kind of largely untouched? Dr. Fumiko Chino: I think you are right in that what we know from what industry will sponsor versus what the federal government will sponsor, that the federal government really helps make up the gap to really make those advancements that save lives, that lead to more birthdays, that advance our knowledge and our capacity for providing more cures and more successful futures for our patients. I always like pointing to the de-escalation research, which is, and this is not to dig pharma, but no pharmaceutical company is going to run a trial that says you can give less of their drug, right? It just does not make sense for the business end of the science. And so, thinking about how to right-size treatments, how to do more with less, that really is the purview of the federal government. Dr. Monty Pal: Absolutely. Absolutely.  I am going to shift gears here and bring up another abstract that I found to be quite intriguing, and this relates to reimbursement of expenses, et cetera, for clinical trials. This is an abstract from Courtney Williams and team. It brings to mind the importance, I think, of recognizing the hardships that patients take on by clinical trials, but I also would love for you to comment on that sort of fine line between reimbursement for expenses and then, you know, sort of undue enticement. It is a challenging balance there. But give me your reflections on this abstract. Dr. Fumiko Chino: Absolutely. You are speaking about Dr. Williams' Abstract 93 from the Alabama group, and Alabama actually has this incredible group of health services researchers which is, are doing really important work in this space. What this trial shows is that, you know, it is a small pilot study, it is 30-something patients that received some support primarily for their travel and additional expenses related to their clinical trial participation for breast cancer. It showed that the money helps, and I think what we all know is that it is expensive to participate in clinical trials. It requires additional visits. It often requires some significant travel burden for our patients, and I do not feel that money reimbursement for clinical trial expenses is an inducement. Nobody participates in a clinical trial to get the money for their gas, right? We know that our patients are making some pretty significant sacrifices in order to participate in clinical trials, and what this type of program does is just actually reimburse them for their outlaying of funds.  And I loved this trial because the patients were actually given $1,000 a month for the first 4 months of their trial participation, and what the study showed is that the patients were using it for things like travel-related food, for things like transportation, caregiver expenses, or even some of their out-of-pocket medical expenses like cost sharing or prescriptions. And that they said that overall, the reimbursement really made a difference in terms of their capacity for staying on the clinical trial. Because we know our clinical trials really are not able to enroll the full diversity of patients that often have a disease, and that the patients that are at biggest risk for a health care disparity or a gap in care are also the least likely to enroll in a clinical trial.  Programs like this are an essential part of showing how financial toxicity can be overcome with pretty straightforward assistance to patients to help reimburse them for the things that they are already taking out of their pocket, for parking costs, for that $10 soup that they buy at the cancer center, for those additional expenses that we are, unfortunately, putting on them. Dr. Monty Pal: Very well said. And you know, I have started to dabble in clinical trials looking at CAR T-cell therapies for kidney cancer, and I have to tell you, it is just insane the amount of cost that a patient would have to take on to comply with the stipulations for some of these novel therapies. We require that they stay within 30 minutes of the facility for 28 days, and unless we are compensating for some of that, I mean, how can one afford a hotel stay that is that long? I mean, it is just, it is unprecedented, and it would certainly provide a huge barrier to many patients who would otherwise enroll. Really well said. I also wanted to bring up another financially driven topic, and treating renal cell, again, I would say the vast majority, 90% plus of my patients in clinic are on oral drug therapies. And I cannot tell you how often a patient will show up in my practice and say, "Doc, I have got 15 days out of this 30-day prescription left. What do I do with it?" You know, or some come with pill bottles from a deceased loved one. And it is so frustrating to say, "Take it to the pharmacy and they will just get rid of it for you." But sounds like there is an abstract from Dr. Mackler, Abstract 102, that seems to address this topic quite well. Am I right? Dr. Fumiko Chino: Absolutely. This presentation, I was the most excited about seeing because this group, which helps run a cancer drug repository, theirs is called YesRx, presented their data from the last approximately two years of running this repository, and they were able to show incredible benefit for their patients in Michigan. And it is a really straightforward program. It is run by pharmacists. It has support from the legislation in Michigan. And what they were able to show is that they repurposed medications that would otherwise have been discarded. They delivered them directly to the oncologist, which then actually dispersed them to the patients. They helped 1,000 patients in less than two years. They saved them millions of dollars, over $15 million presented in the abstract. And it is just a win-win-win because I know that patients actually, and sometimes patient caregivers, they feel very sad to have spent a lot of money out of pocket for their medication, and then if they have a dose reduction or, obviously, you know, if the surviving spouse then has to get rid of their medication, just dispose of them, it is very disheartening. And this is a way of kind of reclaiming power for patients. So they were able to accept donations from all over the state of Michigan and then also help over 1,000 patients. And so, it is a phenomenal program. Dr. Monty Pal: Just wild when I came across the dollar amounts, right, that they were saving. It just, it seems like a place that, you know, we just have to look, as cancer centers, right, and really take this on. Just brilliant. On that same theme of cost savings and so forth, you know, I think there has been a lot of focus on what recent policies have done in the context of us having access to therapies and so forth. And one of the topics that has come up is the Inflation Reduction Act and how changes pertaining to the IRA have really played a role in one's ability to take on some of these expensive prescriptions. And I believe John Lin and colleagues tackled that issue in Abstract 97. Could you comment on that, Fumiko? Dr. Fumiko Chino: Absolutely. Dr. Lin is one of my colleagues here at MD Anderson, so I know him very well, and he has been doing really phenomenal work over the last several years with looking at drug affordability and access. And what his analysis shows is that for patients, after the Inflation Reduction Act's cap on out-of-pocket expenses, is that it really did show that out-of-pocket expenses decreased. So what the Inflation Reduction Act did is that it eliminated the 5% co-insurance and placed this $2,000 cap on out-of-pocket expenses. And what that led to for these patients that were not able to have the low-income subsidy is that there were lower costs, and that there was a lower rate of drug abandonment, meaning that the prescription was not refilled. There was also a lower rate of unfilled prescriptions as well. And I think that it shows that health policy really can improve access to care. I think the flip side of the fact that the IRA, this policy, really did seem to help people is that what his research showed is that actually, even with the benefits of this cap, is that actually it is still really high in terms of the rate of people who are not able to fill their prescriptions or that completely abandon them over time. And that unfortunately, even with this change, that over half of people without the low-income subsidy were potentially not getting the full benefit of their medications because they were not able to afford them. And so I think it really kind of highlights that we still need to do more work about making drugs affordable. Dr. Monty Pal: Indeed, indeed. And I mean, in a setting like this, I mean, I think it is important to recognize that $2,000 is a lot, it is a big chunk of change, right, for a lot of families in the U.S. What do you think of the prospect of, like, decreasing that cap? Is that something that from a policy standpoint you would be supportive of? Dr. Fumiko Chino: Well, so something that is a real option for patients on Medicare is there is something called the Medicare Prescription Payment Plan, and what it allows you to do is actually prorate the $2,000 over the whole year. And so instead of having to pay $2,000 as soon as you fill your prescription, because you are going to have, if you have an expensive medication, it is essentially you have to pay the $2,000 in January, right? It allows you to prorate it, so essentially $170 a month, and that comes to you as like a regular bill. And I think that as rolled out as part of the IRA is a really lovely way of thinking about how do we make these payments more stable over time, so it is not a huge hit sort of at the beginning of the year. And I think that alone actually can make a difference in terms of trying to help make sure that people can actually get their medications. Dr. Monty Pal: That is an excellent tip. Excellent tip.  We are going to shift gears entirely. We have been talking a lot about the dollars and cents of things and talk about an abstract from Sophia Smith and colleagues. So this is Abstract 550 at your meeting. And this hinged on a program of sorts to deal with post-traumatic stress disorder. We do not often think about PTSD in the vernacular for oncology patients, but indeed, I mean, it is something that they must face, especially in the context of long-term survivorship. Can you talk a little bit about Dr. Smith's abstract? Dr. Fumiko Chino: Absolutely. I love this work from Dr. Smith, who is at Duke. She worked with Dr. Applebaum, who was my old colleague at Memorial Sloan Kettering. And this group of researchers really is trying to figure out how to best support people into survivorship so that they can actually thrive. And their patient population for this work was actually people who received stem cell transplant, and they focused on people who had PTSD symptoms. And what they were able to show through this SMART design, which is essentially this serial, multiple randomized trial, so everyone got randomized upfront to either usual care or this app, so this digital app that actually helped coach people through cancer distress. And then for the people who were non-responders, they were then additionally randomized to either the app plus coaching or a therapist versus the cognitive behavioral therapy or CBT.  And what they were able to show is that, number one, anyone who had the app seemed like they did better than those who did not start the path with the app. But then the additional help of either the therapist or the coach or the CBT made additional benefit over time. And so, I think this shows a really nice stepped care, which is you can potentially have some right-sizing of treatments cost saving, if we sort of give everyone the app, which is, I think, overall pretty low cost. And that for the people who do not get the full benefit from the app, then you can think about these maybe more tailored approaches, the therapist, the coach, the CBT, but that some people actually just respond to the app. And I think it allows us to, again, right-size the care for our patients. And I think it is really innovative to think about how technology can help improve access to care in the setting of something like PTSD. Dr. Monty Pal: Brilliant summary. Brilliant summary.  Gosh, it looks like such an exciting meeting this year. Congratulations on a terrific program for the ASCO Quality Care Symposium. I know you played a huge role in developing it, and thanks for sharing your insights on the ASCO Daily News Podcast. Dr. Fumiko Chino: No, I really appreciate you having me. ASCO Quality is my favorite meeting of the year. You know, it is really a phenomenal meeting, and I am so excited for next year in Boston in 2026. Dr. Monty Pal: Awesome. And thanks to our listeners too. You are going to find links to all the abstracts that we discussed today in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. More on today's speakers: Dr. Sumanta (Monty) Pal  @montypal Dr. Fumiko Chino @fumikochino Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures of Potential Conflicts of Interest: Dr. Monty Pal:     Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Fumiko Chino:  Consulting or Advisory Role: Institute for Value Based Medicine Research Funding: Merck

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

In this episode of ASTCT Talks, we're excited to share a special feature from the Pharmacy Focus: Oncology Edition podcast in honor of American Pharmacists Month, featuring members of ASTCT Pharmacy SIG. Expert pharmacists share key insights on BCMA bispecifics, CAR T-cell therapies, and other cellular treatments for multiple myeloma. Moderated by Ryan Shaw, PharmD, of the University of North Carolina at Chapel Hill, the discussion features Sara Ann Scott, PharmD, of Emory Winship Cancer Institute, and Kelley Julian, PharmD, of the University of Utah Huntsman Cancer Institute. Together, they explore treatment sequencing strategies for cellular therapies, with a focus on ciltacabtagene autoleucel and idecabtagene vicleucel.

Drew Ann Long realized there was nothing in regards to shopping carts for the physically disabled. She shares the incredible story of "Caroline's Cart," (available in stores now) that helps families perform their shopping duties with dignity.

Reacting to Greg and Cart's top 10 backcourts in college basketball! Reacting to Greg and Cart's top 10 wing duos in college basketball! Reacting to Greg and Cart's top 10 frontcourts in college basketball! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! PRESENTED BY: Duncan Mechanical Solutions - heating and air conditioning, plumbing, kitchen and bath remodeling and more for Northeast Indiana and Southern Michigan. Go to duncanmechanicalsolutions.com for more. PRESENTED BY: Clara Kate Creations (@ClaraKateCreations on social media) - designing custom and personal sports apparel for your little ones! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 10, 2025. In this episode: biopharma financing regaining optimism; larger CAR-T indications to strain healthcare capacity; Galderma punching above weight in dermatology; Amgen's direct-to-patient Repatha program; and Datroway's survival success in breast cancer. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-JZ326HAB2ZHB7E3Z5PNIUBITQQ/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

The Alan Cox Show

The Alan Cox ShowSee omnystudio.com/listener for privacy information.

Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the reasons you want to pay particular attention to your 2026 health insurance options. As the U.S. federal government shutdown enters its third week, we're reviewing some of the ways that the shutdown may affect someone living with MS. And we're giving you a reminder about how you can add your voice and share your story of living with MS with the FDA by participating in the Shaping Tomorrow Together initiative. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A first-hand account of an important clinical trial, open enrollment begins, and how the government shutdown may affect people with MS  :22 Open enrollment for Medicare and Marketplace enrolees begins  :22 How the federal government shutdown could affect people living with MS  4:29 Your opportunity to tell the FDA what it's like to live with MS  8:57 Jan Janisch-Hanzlik shares her experience participating in a CAR-T cell therapy clinical trial, and how the treatment has impacted her MS  11:28 Share this episode  31:38 Next week's episode  31:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/424 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 424 Guest: Jan Janisch-Hanzlik Privacy Policy

In this inspiring episode of Healthy Mind, Healthy Life hosted by Avik Chakraborty, entrepreneur and coach Jennie Blackwood opens up about the truth behind burnout, motherhood, and business growth. From turning a snack cart idea into a six-figure business to building a global coaching brand, Jennie reveals the hidden costs of hustle culture and how she rebuilt her life around sustainable success. This conversation dives deep into what it really means to thrive without burning out. Jennie shares raw lessons from her own experience — the collapse that forced her to redefine success, how setting boundaries saved her business, and why mindset and self-care are just as critical as marketing strategy. Perfect for entrepreneurs, moms, and creators, this episode challenges the myth that burnout is the price of ambition and reminds us that true success comes from alignment, not exhaustion.   About the Guest  :   Jennie Blackwood is a serial entrepreneur, influencer, and mom of four who built a viral snack cart business that evolved into a six-figure digital coaching empire. Through her platform Cart to Cashflow, Jennie empowers women worldwide to launch and scale profitable businesses without sacrificing their health, family, or peace of mind. Her approach blends practical business strategy with deep mindset transformation — helping women replace burnout with balance and fear with focus.     Key Takeaways: Burnout isn't a badge of honor — it's a warning signal. Recognize the early signs before they derail your vision. Boundaries are a business strategy. Learning to say no is part of saying yes to sustainability. Rest fuels creativity and clarity — not laziness. Self-care is an investment in your long-term performance. Hustle culture is outdated. Digital systems, support, and community can replace constant overwork. Your “why” keeps you grounded. Let it guide your decisions, especially when business gets tough. You are capable of building success on your own terms — one intentional step at a time.   Connect with the Guest   Instagram: socialgraze.charcuterieWebsite: promo.jennieblackwood.com/DM Jennie directly for collaborations or coaching inquiries.   Want to be a guest on Healthy Mind, Healthy Life?   DM on PodMatch — Send a message to Avik Chakraborty

Would You Swap the Noisy Cart by Maine's Coast 93.1

On today episode, Andy & DJ discuss ICE rolling Portland protester away on flatbed cart as Trump says city is burning to the ground, a bloody Mark Sanchez seen stumbling down Indianapolis sidewalk after being stabbed in fight with grease truck driver, and a brand new segment of AI or Nah.

Scott's old Mr. Show buddy Bob Odenkirk returns to talk about Comic Relief 8, the finale of Better Call Saul, and his future focusing on himself. Then, celebrity chef Bobby Flay stops by to talk about his new cooking show. Plus, lawyer Italiano Jones returns to fight for Scott in a mock trial. Originally released as episode 769 on 08/07/2022. Don't forget to check out the Comedy Bang! Bang! Action Figures at shop.figurecollections.com and go to actionfigureseller.com for international purchases. If you want more great episodes of Comedy Bang! Bang! become a subscriber at comedybangbangworld.com. We have all of the past episodes from the archives, every live show, ad-free new episodes, and original shows like CBB Presents and Scott Hasn't Seen. Find more great Comedy Bang! Bang! merch at https://www.podswag.com/collections/comedy-bang-bang Get access to all the podcasts you love, music channels and radio shows with the SiriusXM App! Get 3 months free using this show link: https://siriusxm.com/cbb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This month, the gals invite Steven Ray Morris on to gab about cats in baskets, pettiness with a capital “pee,” the cutest little classroom assistant, unicorn permits, chimp fads, and Lucy's really cool great aunt. Tune in now for September's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.